Navigation Links
Recent Study Reveals Physicians Prefer Topical Delivery for Drug Delivery Technology, Such as a Transdermal Patch
Date:7/25/2013

.

Alliqua is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.

Alliqua currently markets its new line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal® brand. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne PA, allows Alliqua to aggressively develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.

For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit: http://ir.stockpr.com/alliqua/email-alerts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the U.S. Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "inten
'/>"/>

SOURCE FN Media Group LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lex Kogan, Ibogaine Developer, Celebrates Recent CDC Panel
2. iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza
3. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
4. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
5. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
6. The MED Group Announces New Agreement with CareCentrix Effective May 1, 2013
7. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
8. The race toward an interferon free world: The current field of Hepatitis C Virus treatment research, including recent financial deals
9. Accuray Provides Clarification on Recently Initiated Voluntary Recalls
10. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
11. Cardium Presents Year-End 2012 Financial Results And Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Oct. 18 Findings from the PRECiSE 3 (P3) ... demonstrating the longest continuously running maintenance trial for an ... 2010 Annual Scientific Meeting of the American College of ... 15 – 20.  Additionally, long-term efficacy data from the ...
... technology world moves to Basking Ridge, NJ when " 2010 ... Agency (KOTRA), kicks off later this month. The conference is ... seeking the most innovative and creative technology in the U.S. ... EDT (US & Canada) at the Dolce Hotels and Resorts. ...
Cached Medicine Technology:UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 2UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 3UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 4UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 5UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 6UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 8UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 9UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 10UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 11Top U.S. and Korean Companies to Converge at 2010 Global Partnering Day 2
(Date:7/11/2014)... 2014 AngelWeddingDress is now providing worldwide ... summer collections ”. When it comes to buying summer ... AngelWeddingDress with the unlimited stock of beautiful wedding gowns. ... its wonderful summer wedding gowns. , The company’s ... to keep pace with the newest fashion trends. The ...
(Date:7/11/2014)... American Farmer is proud to announce ... 15, 2014, at 8:30 am ET. , In this ... which are designed and formulated for use on a ... these products help the crop realize its maximum genetic ... grown. , The show also features UniSouth Genetics, a ...
(Date:7/11/2014)... 11, 2014 Alliance Labs announced that ... Innovations with Ed Begley Jr, airing later this year ... , In this episode, Innovations will explore DocuSol® Kids, ... sodium in polyethylene glycol base designed to give adolescents ... formulation functions as a hyperosmotic laxative by drawing water ...
(Date:7/11/2014)... 11, 2014 College athletes experiencing in-season ... of injury, but developed recurrent instability in 63% of ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... in providing the most optimal treatment plans for injured ... anterior shoulder instability event, and found that 33 (73%) ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... workers in the United States has risen, so has ... ,According to Vanderbilt infectious disease experts Timothy R. ... be provided to health care workers with latent TB ... particularly if they meet certain high-risk criteria. ...
... researchers has discovered a new protein called as P2 ... epithelial cells// that regulates the allergic airway inflammation. ... study that the adipocyte/macrophage fatty acid–binding protein aP2, which ... of fatty acids and has been previously linked to ...
... the open access journal Substance Abuse Treatment, Prevention and policy ... training treats the alcohol dependent patients better for a long ... by trained GPs who abstain from drinking alcohol is more ... basic training alone at the medical school. Also the ...
... duvets used by most Britons are packed with dust mites, fungus ... duvets it was found to contain up to 20,000 live house ... analysis of an 11-year unwashed duvet revealed over an ounce and ... faeces. ,In addition it was found that more than ...
... new research, the risk of heart diseases is reduced on ... the University of Bristol in the UK and colleagues conducted ... between 44 to 65, and found a direct association between ... of the thickness of blood vessel walls that is used ...
... Danish researchers, in their new studies have concluded that ... suffer from a serious heart condition when compared to ... ,Research by Kirsten Melgaard Nielsen, Ph.D., and colleagues, of ... after obtaining data on 138,000 adults between the ages ...
Cached Medicine News:Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Dust mites use Duvets as their Haven 2Health News:Long Legs Reduces The Chances Of Heart Disease 2Health News:Significant Increase In Heart Diseases Found In Older People Living Alone 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: